SYRE Aug 2024 30.000 call
| Previous close | 2.0500 |
| Open | N/A |
| Bid | 0.1000 |
| Ask | 5.0000 |
| Strike | 30.00 |
| Expiry date | 2024-08-16 |
| Day's range | 2.0500 - 2.0500 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
PR NewswireSpyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of SPY001, its Novel Half-life Extended anti-α4β7 Antibody, for the Treatment of Inflammatory Bowel Disease
Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of Inflammatory Bowel Disease ("IBD"), today announced that it has initiated dosing of healthy volunteers in its first clinical trial of SPY001, an investigational novel half-life extended anti-α4β7 monoclonal antibod
- PR Newswire
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for the treatment of Inflammatory Bowel Disease ("IBD"), today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grants of stock options to purchase an aggregate of 83,000 shares of common stock of Spyre to 3 non-executive emplo
- PR Newswire
Spyre Therapeutics to Participate in the Jefferies Global Healthcare Conference
Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for the treatment of Inflammatory Bowel Disease ("IBD"), today announced that management will participate in a fireside chat and investor meetings at the Jefferies Global Healthcare Conference. Details of the fireside are as follows:
